Asparaginase Escherichia coli

Generic Name: Asparaginase Escherichia coli

Brand Names: Rylaze, Spectrila

Drug Type: Biotech

Chemical Formula: -

CAS Number: 9015-68-3

Unique Ingredient Identifier: G4FQ3CKY5R

Background: Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...

Indication: Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL)

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-09-01

Last Posted Date: 2017-02-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1970

Registration Number: NCT00002744

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸
Children's Hospital and Medical Center - Seattle, Seattle, Washington, United States

and more 31 locations

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002471

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2

Conditions: Leukemia

First Posted Date: 2004-08-23

Last Posted Date: 2013-09-20

Lead Sponsor: Grupo Argentino de Tratamiento de la Leucemia Aguda

Registration Number: NCT00002499

Locations: 🇦🇷
Grupo Argentino de Tratamiento de la Leucemia Aguda, Buenos Aires, Argentina

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Neutropenia
Thrombocytopenia

First Posted Date: 2004-07-29

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT00002665

Locations: 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 80 locations

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-01

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002691

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: leucovorin calcium
Drug: liposomal cytarabine
Drug: mercaptopurine
Drug: mesna
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: thiotepa
Drug: vincristine sulfate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-01

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00002704

Locations: 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 67 locations

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-06-16

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Registration Number: NCT00002785

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 30 locations

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-05-20

Last Posted Date: 2013-12-19

Lead Sponsor: United Kingdom Children's Cancer Study Group

Target Recruit Count: 100

Registration Number: NCT00003423

Locations: 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: melphalan
Drug: thioguanine
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-05-20

Last Posted Date: 2014-07-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 35

Registration Number: NCT00004056

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States

and more 17 locations

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: G-CSF
Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Drug: Allopurinol

First Posted Date: 2004-05-20

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 163

Registration Number: NCT00003700

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 47 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy